Company intelligence / Profile preview

Galobio

Buenos Aires, Buenos Aires, Argentina

Ownership: Private
Development stage: Other

Overview

Galobio is a biotechnology company focused on the development of therapies targeting Galectin-1, a key protein involved in immune regulation and vascularization. Founded by Dr. Gabriel Rabinovich, the company builds on over 30 years of research into how Galectin-1 helps tumors evade the immune system and how its modulation can treat inflammatory conditions. Their approach includes developing monoclonal antibodies to block Galectin-1 in oncology and using Galectin-1 variants to treat autoimmune diseases. Galobio represents a significant effort to translate Argentine scientific excellence into global therapeutic products.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Monoclonal antibodyRecombinant protein
Industry: Biotech

Partnerships

CONICETFundación Sales

Beyond the preview

Go deeper on Galobio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galobio.

Explore the full profile